Wikidata

(Q61907040)

English

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

clinical trial

In more languages

Statements

short name
IDEALL (English)
0 references
title
An Open-Label, Single-Arm Phase II Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-Naive Multiple Myeloma Patients Non-Eligible for Autologous Stem-Cell Transplantation (English)
0 references
start time
30 May 2019
0 references
end time
30 June 2021
0 references
number of participants
40
0 references
research intervention
glycine
0 references
thalidomide
0 references
dexamethasone acetate
0 references
(RS)-cyclophosphamide
0 references
ixazomib
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61907040&oldid=2133967408"